Latest Period
Q1 2026
Security Snapshot
RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) Institutional Ownership
CUSIP: 75382E208
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$58.02
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- RAPT
- Shares outstanding
- 27,748,559
- Reported price per share
- $58.02
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 0
- Total reported value
- $0
- Share change
- -26,013,406
- Value change
- -$881,075,501
- Number of holders
- 0
Security identity
Issuer context
Latest holder snapshot
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- RAPT - RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 75382E208.
- 0 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 99 to 0 between Q4 2025 and Q1 2026.
- Reported value moved from $921,288,979 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 0 institutions filings for Q1 2026.
Security key
75382E208
Latest holder period
Q1 2026
13F holders
0
13D/G owners
6
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75382E208:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
RAPT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ForGrowth III PA B.V. | 7.4% | $47,291,008 | 1,833,333 | ForGrowth III PA B.V. | 23 Oct 2025 | |||
| Redmile Group, LLC | 9.9% | $14,934,463 | 1,765,303 | Redmile Group, LLC | 30 Jun 2025 | |||
| RTW INVESTMENTS, LP | 5.9% | $55,041,487 | 1,637,165 | RTW Investments, LP | 31 Dec 2025 | |||
| VANGUARD GROUP INC | 4.2% | $17,958,239 | 696,188 | The Vanguard Group | 30 Sep 2025 | |||
| Nantahala Capital Management, LLC | 3.8% | -33% | $16,074,692 | -$8,467,788 | 623,282 | -35% | Nantahala Capital Management, LLC | 30 Sep 2025 |
| Deep Track Capital, LP | 0.4% | $3,713,262 | 110,448 | Deep Track Capital, LP | 31 Dec 2025 |
As of 31 Mar 2026, 0 institutional investors reported holding 0 shares of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT). This represents 0% of the company’s total 27,748,559 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Latest
Q1 2026
Rows shown
1-4 of 4